Shire Stock Hits New 52-Week High (SHPG)

NEW YORK ( TheStreet) -- Shire (Nasdaq: SHPG) hit a new 52-week high Friday as it is currently trading at $102.11, above its previous 52-week high of $102.04 with 205,577 shares traded as of 11:31 a.m. ET. Average volume has been 615,300 shares over the past 30 days.

Shire has a market cap of $18.33 billion and is part of the health care sector and drugs industry. Shares are up 7.7% year to date as of the close of trading on Thursday.

Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM).

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Shire Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..
null

If you liked this article you might like

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment

Shire Gains as it Seeks European Approval For Dry Eye Treatment

Tesla and Apple Better Deliver Big-Time or Look Out Below -- Week Ahead